|DB00457||Prazosin||This drug is indicated for the treatment of hypertension (high blood pressure). Prazosin can be given alone or given with other blood pressure-lowering drugs, including diuretics or beta-adrenergic blocking agents [FDA label].
Prazosin does not negatively impact lung function, and therefore may be used to manage hypertension in patients who are asthmatic or patients with chronic obstructive lung disease (COPD)[A176630].|
|DB00524||Metolazone||For the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.|
|DB00530||Erlotinib||Erlotinib is indicated for:
- The treatment of metastatic non-small cell lung cancer (NSCLC) with tumors showing epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations [FDA label].
- In combination with first-line treatment for patients diagnosed with locally advanced, unresectable or metastatic pancreatic cancer [FDA label].
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy. [FDA label]|
|DB00590||Doxazosin||For treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.|
|DB01157||Trimetrexate||For use, with concurrent leucovorin administration (leucovorin protection), as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS). Also used to treat several types of cancer including colon cancer.|
|DB01162||Terazosin||Terazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension[FDA Label].|
|DB04833||Methaqualone||For the treatment of insomnia, and as a sedative and muscle relaxant.|
|DB04866||Halofuginone||For the treatment of scleroderma, cancer, and restenosis.|
|DB05232||Tetrodotoxin||For the treatment of chronic and breakthrough pain in advanced cancer patients as well as for the treatment of opioid dependence.|
|DB06350||Elinogrel||Investigated for use/treatment in cardiovascular disorders and myocardial infarction.|
|DB08882||Linagliptin||Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise[FDA Label]. It should not be used to treat type I diabetes or in diabetic ketoacidosis[FDA Label].|
|DB09054||Idelalisib||Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.|
|DB11963||Dacomitinib||Dacomitinib is indicated as the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as verified by an FDA-approved test.[L4812]
Lung cancer is the leading cause of cancer death and NSCLC accounts for 85% of lung cancer cases. From the cases of NSCLC, approximately 75% of the patients present a late diagnosis with metastatic and advanced disease which produces a survival rate of 5%. The presence of a mutation in EGFR accounts for more than the 60% of the NSCLC cases and the overexpression of EGFR is associated with frequent lymph node metastasis and poor chemosensitivity.[A40018, A19201]|